Incyte

Last updated
Incyte Corporation
Type Public company
Industry pharmaceutical company
Founded2002;21 years ago (2002)
Headquarters
Wilmington, Delaware, U.S.
Key people
Hervé Hoppenot (CEO, chairman & president)
RevenueIncrease2.svg US$2.99 billion (2021)
Increase2.svg US$586 million (2021)
Increase2.svg US$949 million (2021)
Total assets Increase2.svg US$4.93 billion (2021)
Total equity Increase2.svg US$3.77 billion (2021)
Number of employees
2,094 (December 2021)
Website incyte.com
Footnotes /references
[1]

Incyte is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, [2] and Morges, Switzerland. [3] The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 [4] and Incyte Genomics, Inc. of Delaware. [5] The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. [6]

Contents

Incyte Corporation currently develops and manufacturers prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.

History

In 2014, Incyte named Hervé Hoppenot president and CEO, and in 2015 he was appointed chairman of the Board of Directors. [7] [8] Hoppenot had previously served as the president of Novartis Oncology; he had been with Novartis since 2003. [8]

In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million. [9]

In January 2020, Incyte signed a collaboration and license agreement for the global development and commercialization of tafasitamab with MorphoSys. [10] On March 3, 2020, the agreement received antitrust clearance and thus became effective. [11]

Pharmaceuticals

Incyte Corporation currently has seven marketed and co-marketed pharmaceutical products, including Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix) , Opzelura (Ruxolitinib), Tabrecta (capmatinib), Olumiant (Baricitinib), and Iclusig (ponatinib). [12] [13] In 2013, Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is marketed under the brand name Tabrecta. [14]

As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly. [15] [16] It gained EU approval in February 2017. [17] In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety. [18] [19] In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis under the brand name Olumiant. [20] [21]

As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo). [22] [23]

Related Research Articles

Adalimumab, sold under the brand name Humira, among others, is a monoclonal antibody used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. It is administered by subcutaneous injection.

<span class="mw-page-title-main">Lankenau Institute for Medical Research</span>

Lankenau Institute for Medical Research (LIMR), founded in 1927, is a nonprofit, biomedical research institute located on the campus of Lankenau Medical Center in Wynnewood, Pennsylvania, serving as the research division of the Main Line Health System in suburban Philadelphia. LIMR focuses on studies of cancer, cardiovascular, autoimmune, gastrointestinal and other diseases. It houses a center for population health research.

Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, a severe form of arthritis in children, and COVID‑19. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. Tocilizumab was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.

<span class="mw-page-title-main">ARIAD Pharmaceuticals</span> Defunct oncology company

ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients.

MorphoSys AG is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.

A Janus kinase inhibitor, also known as JAK inhibitor or jakinib, is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family of enzymes, thereby interfering with the JAK-STAT signaling pathway in lymphocytes.

<span class="mw-page-title-main">Ruxolitinib</span> Medication

Ruxolitinib, sold under the brand name Jakafi among others, is a medication used for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative neoplasm that affects the bone marrow; polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; and steroid-refractory acute graft-versus-host disease. Ruxolitinib is a Janus kinase inhibitor. It was developed and marketed by Incyte Corp in the US under the brand name Jakafi, and by Novartis elsewhere in the world, under the brand name Jakavi.

<span class="mw-page-title-main">Secukinumab</span> Monoclonal antibody against IL-17 used for treatment of psoriasis

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.

<span class="mw-page-title-main">Baricitinib</span> Chemical compound

Baricitinib, sold under the brand name Olumiant among others, is an immunomodulatory medication used for the treatment of rheumatoid arthritis, alopecia areata, and COVID-19. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.

Guselkumab, sold under the brand name Tremfya, is a monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis.

Advanced Accelerator Applications is a France-based pharmaceutical group, specialized in the field of nuclear medicine. The group operates in all three segments of nuclear medicine to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases.

<span class="mw-page-title-main">Ceritinib</span> ALK inhibitor for treatment of non-small-cell lung cancer

Ceritinib is a prescription-only drug used for the treatment of non-small cell lung cancer (NSCLC). It was developed by Novartis and received FDA approval for use in April 2014..Ceritinib is also sold under the brand name Spexib in few countries by Novartis.

<span class="mw-page-title-main">Filgotinib</span> Chemical compound

Filgotinib, sold under the brand name Jyseleca, is a medication used for the treatment of rheumatoid arthritis (RA). It was developed by the Belgian-Dutch biotech company Galapagos NV.

<span class="mw-page-title-main">PD-1 and PD-L1 inhibitors</span> Class of anticancer drugs

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitor anticancer drugs that block the activity of PD-1 and PDL1 immune checkpoint proteins present on the surface of cells. Immune checkpoint inhibitors are emerging as a front-line treatment for several types of cancer.

<span class="mw-page-title-main">Epacadostat</span> Chemical compound

Epacadostat is an investigational drug for cancer. Epacadostat is an inhibitor of indoleamine 2,3-dioxygenase-1 (IDO1). Epacadostat inhibits IDO1 by competitively blocking it, without interfering with IDO2 or tryptophan 2,3-dioxygenase (TDO). It has antitumor activity in some models, though is most effective when combined with other immunotherapy agents.

<span class="mw-page-title-main">Capmatinib</span> Chemical compound

Capmatinib, sold under the brand name Tabrecta, is an anticancer medication used for the treatment of metastatic non-small cell lung cancer whose tumors have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR.

Otilimab is a fully human antibody which has been developed by the biotechnology company MorphoSys. It can also be referred to as HuCAL antibody, HuCAL standing for Human Combinatorial Antibody Library and being a technology used to generate monoclonal antibodies. Otilimab is directed against the granulocyte-macrophage colony stimulating factor (GM-CSF), a monomeric glycoprotein functioning as a cytokine promoting both proliferation and activation of macrophages and neutrophils.

Ianalumab is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus.

Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

BeiGene is a global biotechnology company that specializes in the development of drugs for cancer treatment. Founded in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in Asia, North America, Australia and Europe. Beigene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

References

  1. ↑ "Incyte Corp. 2021 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. 8 February 2022.
  2. ↑ "INCY". www.nasdaq.com. Retrieved 2021-07-26.
  3. ↑ "Incyte to establish European headquarters in Geneva". 15 July 2020. Retrieved 12 September 2021. New facility to serve as European base for Incyte's drug development operations, and provides efficient access to key clinical trial experts and institutions.
  4. ↑ Scott Goss (2 Mar 2015). "Incyte is Delaware Bio Company of the Year, again". delawareonline.com. Retrieved 2 Mar 2015.
  5. ↑ "Certificate of Ownership and Merger". www.sec.gov. Retrieved 2021-07-26.
  6. ↑ "Headquarters - Pharmaceutical Research & Development | Incyte". www.incyte.com. Retrieved 2021-07-27.
  7. ↑ "Leadership | Incyte". www.incyte.com. Retrieved 2021-07-26.
  8. 1 2 "People". Gen. Eng. Biotechnol. News (paper). Vol. 34, no. 4. February 15, 2014. p. 41.
  9. ↑ "Incyte to Co-Develop Hengrui's SHR-1210 in Up-to-$795M+ Deal". Genetic Engineering & Biotechnology News. 2 September 2015.
  10. ↑ "MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab".
  11. ↑ "MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab".
  12. ↑ "incy_Current folio_10K". www.sec.gov. Retrieved 2021-07-26.
  13. ↑ "portfolio.pdf" (PDF). www.incyte.com. Retrieved 2022-12-18.
  14. ↑ "Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development | Business Wire". www.businesswire.com. 29 April 2013. Retrieved 2015-12-29.
  15. ↑ "Lilly, Incyte Treatment Shows Positive Results". www.insideindianabusiness.com. 9 Dec 2014. Archived from the original on 8 March 2015. Retrieved 2 Mar 2015.
  16. ↑ "Baricitinib" (PDF). Statement on a nonproprietary name adopted by the USAN council. American Medical Association.
  17. ↑ "Olumiant: Authorisation details". European Medicines Agency. 16 March 2017.
  18. ↑ Ramsey, L (17 April 2017). "The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling". Business Insider.
  19. ↑ Grant, Ch (14 April 2017). "Surprise FDA Rejection Will Sting This Biotech". The Wall Street Journal.
  20. ↑ Research, Center for Drug Evaluation and (2019-02-09). "Drug Trials Snapshots: OLUMIANT". FDA.
  21. ↑ "Drug Approval Package: Olumiant (baricitinib)". www.accessdata.fda.gov. Retrieved 2021-07-27.
  22. ↑ Brochez, L; Chevolet, I; Kruse, V (May 2017). "The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy". European Journal of Cancer. 76: 167–182. doi: 10.1016/j.ejca.2017.01.011 . PMID   28324751.
  23. ↑ Tracy Staton (Apr 3, 2017). "Racing in lung cancer again (or still), Merck and BMS expand Incyte combo trials". FiercePharma.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.